Breaking: FDA approves Eli Lilly's obesity drug Zepbound

Eli Lilly's blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity.

Log In    Try STAT+ Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound By Elaine Chen November 8, 2023 Darron Cummings/AP Eli Lilly's blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been approved by the FDA to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market.   The FDA's long-awaited approval of the drug, which will be marketed under the name Zepbound for obesity, is a major milestone for Lilly. It also introduces stiff competition for Novo Nordisk, which has had to limit starter doses of its obesity treatment Wegovy due to ongoing shortages. READ THE STORY In Case You Missed It Pharma Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies Exclusive How one scientist's determination made Novo Nordisk an obesity-drug powerhouse The Obesity Revolution Here are the dozens of weight loss drugs in development to catch a booming market ALL STORIES STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences   |   Contact Us   |   Advertise With Us